These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 2015114)

  • 1. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?
    Clements GJ; Price-Jones MJ; Stephens PE; Sutton C; Schulz TF; Clapham PR; McKeating JA; McClure MO; Thomson S; Marsh M
    AIDS Res Hum Retroviruses; 1991 Jan; 7(1):3-16. PubMed ID: 2015114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of mutations in the V3 loop of HIV-1 gp120 on infectivity and susceptibility to proteolytic cleavage.
    Schulz TF; Reeves JD; Hoad JG; Tailor C; Stephens P; Clements G; Ortlepp S; Page KA; Moore JP; Weiss RA
    AIDS Res Hum Retroviruses; 1993 Feb; 9(2):159-66. PubMed ID: 8457383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell membrane-associated serine protease, tryptase TL2, binds human immunodeficiency virus type 1 gp120 and cleaves the third-variable-domain loop of gp120. Neutralizing antibodies of human immunodeficiency virus type 1 inhibit cleavage of gp120.
    Niwa Y; Yano M; Futaki S; Okumura Y; Kido H
    Eur J Biochem; 1996 Apr; 237(1):64-70. PubMed ID: 8620895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus.
    Kido H; Niwa Y; Beppu Y; Towatari T
    Adv Enzyme Regul; 1996; 36():325-47. PubMed ID: 8869754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4 activation of HIV fusion.
    Sattentau QJ
    Int J Cell Cloning; 1992 Nov; 10(6):323-32. PubMed ID: 1281202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin activates envelope glycoproteins of HIV type 1 and enhances fusion.
    Ling H; Xiao P; Usami O; Hattori T
    Microbes Infect; 2004 Apr; 6(5):414-20. PubMed ID: 15109955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alanine substitution of two arginines in amino terminus of V3 of SIV disrupts CD4 binding whereas a similar replacement of two amino acids, lysine and arginine, in the carboxyl half of V3 prevents binding of a neutralizing monoclonal antibody.
    Javaherian K; Zuchowski L; Clark FT
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1101-5. PubMed ID: 8554907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of U-937 membrane-associated cathepsin G by GP120 (IIIB) and V3 loop-derived peptides from several strains of HIV-1.
    Avril LE; di Martino-Ferrer M; Brillard-Bourdet M; Gauthier F
    FEBS Lett; 1995 Jul; 367(3):251-6. PubMed ID: 7607317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120.
    Maeda Y; Matsushita S; Hattori T; Murakami T; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2049-54. PubMed ID: 1493053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function.
    Chiou SH; Freed EO; Panganiban AT; Kenealy WR
    AIDS Res Hum Retroviruses; 1992 Sep; 8(9):1611-8. PubMed ID: 1457207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies.
    Potts BJ; Field KG; Wu Y; Posner M; Cavacini L; White-Scharf M
    Virology; 1993 Nov; 197(1):415-9. PubMed ID: 8212576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4.
    Weinberg J; Liao HX; Torres JV; Matthews TJ; Robinson J; Haynes BF
    AIDS Res Hum Retroviruses; 1997 May; 13(8):657-64. PubMed ID: 9168234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
    McCaffrey RA; Saunders C; Hensel M; Stamatatos L
    J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
    Back NK; Smit L; De Jong JJ; Keulen W; Schutten M; Goudsmit J; Tersmette M
    Virology; 1994 Mar; 199(2):431-8. PubMed ID: 8122371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
    Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG
    J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.
    McKeating JA; Shotton C; Cordell J; Graham S; Balfe P; Sullivan N; Charles M; Page M; Bolmstedt A; Olofsson S
    J Virol; 1993 Aug; 67(8):4932-44. PubMed ID: 7687306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.